Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: blood withdrawal.
- Who it may be relevant to
- Registry conditions: Pollen Allergy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
Interventions
- Other blood withdrawal
Blood withdrawal
Primary outcome measures
- Antibody profiling [Time frame: October 2018 - September 2021]
Eligibility criteria
Inclusion criteria
- History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
- Male or female patients older than 18 years
- Written informed consent for providing blood and also to allow experimental manipulation
Exclusion criteria
- Age < 18 years
- Any corticosteroids within the last three days
- Oral corticosteroid therapy within the last ten days
- Parenteral depot corticosteroids within the last three months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- Immunologie Zentrum Zürich — Zurich
Identifiers
NCT: NCT03727399 · 2018-01110